{
    "2018-07-18": [
        [
            {
                "time": "2018-07-17",
                "original_text": "【医药-乐普医疗(300003)】江琦、谢木青：阿托伐他汀钙通过一致性评价，药品业务进入收获期-20180717",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "阿托伐他汀钙",
                        "一致性评价",
                        "药品业务",
                        "收获期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "今日涨停板股票预测：7月18日国企改革概念迎爆发契机",
                "features": {
                    "keywords": [
                        "涨停板",
                        "国企改革",
                        "概念",
                        "爆发契机"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "[买入评级]乐普医疗(300003)：阿托伐他汀通过一致性评价 夯实业绩增长点",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "阿托伐他汀",
                        "一致性评价",
                        "业绩增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "【医药|周小刚】乐普医疗(300003)：阿托伐他汀一致性评价即将获批，有望贡献显著利润增量",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "阿托伐他汀",
                        "一致性评价",
                        "利润增量"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "【东吴晨报0718】【行业】电新【个股】地素时尚、星源材质、乐普医疗",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "东吴晨报",
                        "行业",
                        "个股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "医药生物行业日报：2018年抗癌药医保准入专项谈判将开展",
                "features": {
                    "keywords": [
                        "医药生物",
                        "抗癌药",
                        "医保准入",
                        "专项谈判"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "[推荐评级]医药行业周报：医药反弹有望持续 重点关注业绩增长明确标的",
                "features": {
                    "keywords": [
                        "医药行业",
                        "周报",
                        "反弹",
                        "业绩增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}